Artiva Biotherapeutics (ARTV) Income from Non-Controlling Interests (2024 - 2026)
Artiva Biotherapeutics' (ARTV) quarterly Income from Non-Controlling Interests came in at -$121000.0 in Q1 2026, down 193.8% year-on-year from $129000.0 in Q1 2025, and down 856.25% on a QoQ basis from $16000.0 in Q4 2025.
Artiva Biotherapeutics (ARTV) Income from Non-Controlling Interests (2024 - 2026) Analysis & Trends
Artiva Biotherapeutics (ARTV) has 3 years of Income from Non-Controlling Interests data on file, last reported at -$121000.0 in Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests fell 193.8% year-over-year to -$121000.0 in Q1 2026; TTM through Mar 2026 was -$18000.0, a 91.3% increase from a year earlier, with the FY2025 full-year figure at $232000.0, up 153.09% from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at -$121000.0, down from $16000.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for ARTV reached as high as $217000.0 in Q3 2024 and fell as low as -$467000.0 in Q4 2024.
- Historically, Income from Non-Controlling Interests has averaged -$36222.2 across 3 years, with a median of $2000.0 in 2025.
- Across the five-year window, Income from Non-Controlling Interests soared 227.72% in 2025 and slumped 193.8% in 2026, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at -$467000.0 in 2024, then jumped by 103.43% to $16000.0 in 2025, then plunged by 856.25% to -$121000.0 in 2026.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were -$121000.0 in Q1 2026, $16000.0 in Q4 2025, and $85000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,538.84 Bn | 65,538.56 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 469.46 Bn | 464.67 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.69 Bn | 115.45 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.41 Bn | 61.65 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.84 Bn | 62.84 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | - |
| 10 | Artiva Biotherapeutics | 252.21 Mn | 252.21 Mn | - | -121,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -121,000.00 |
| Dec 31, 2025 | 16,000.00 |
| Sep 30, 2025 | 85,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Mar 31, 2025 | 129,000.00 |
| Dec 31, 2024 | -467,000.00 |
| Sep 30, 2024 | 217,000.00 |
| Jun 30, 2024 | -86,000.00 |
| Mar 31, 2024 | -101,000.00 |